Katelynn S Madill-Thomsen1, Georg A Böhmig2, Jonathan Bromberg3, Gunilla Einecke4, Farsad Eskandary2, Gaurav Gupta5, Luis G Hidalgo6, Marek Myslak7, Ondrej Viklicky8, Agnieszka Perkowska-Ptasinska9, Philip F Halloran10,11. 1. Alberta Transplant Applied Genomics Centre, Edmonton, Alberta, Canada. 2. Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria. 3. Departments of Surgery and Microbiology and Immunology, University of Maryland, Baltimore, Maryland. 4. Department of Nephrology, Hannover Medical School, Hannover, Germany. 5. Division of Nephrology, Virginia Commonwealth University, Richmond, Virginia. 6. Department of Surgery, University of Wisconsin, Madison, Wisconsin. 7. Pomeranian Medical University, Department of Clinical Interventions and Department of Nephrology and Kidney Transplantation, Samodzielny Publiczny Wojewodzki Szpital Zespolony, Szczecin, Poland. 8. Department of Nephrology and Transplant Center, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. 9. Department of Pathology, Medical University of Warsaw, Warsaw, Poland. 10. Alberta Transplant Applied Genomics Centre, Edmonton, Alberta, Canada phallora@ualberta.ca. 11. Department of Medicine, Division of Nephrology and Transplant Immunology, University of Alberta, Edmonton, Alberta, Canada.
Abstract
BACKGROUND: Donor -specific HLA antibody (DSA) is present in many kidney transplant patients whose biopsies are classified as no rejection (NR). We explored whether in some NR kidneys DSA has subtle effects not currently being recognized. METHODS: We used microarrays to examine the relationship between standard-of-care DSA and rejection-related transcript increases in 1679 kidney transplant indication biopsies in the INTERCOMEX study (ClinicalTrials.gov NCT01299168), focusing on biopsies classified as NR by automatically assigned archetypal clustering. DSA testing results were available for 835 NR biopsies and were positive in 271 (32%). RESULTS: DSA positivity in NR biopsies was associated with mildly increased expression of antibody-mediated rejection (ABMR)-related transcripts, particularly IFNG-inducible and NK cell transcripts. We developed a machine learning DSA probability (DSAProb) classifier based on transcript expression in biopsies from DSA-positive versus DSA-negative patients, assigning scores using 10-fold cross-validation. This DSAProb classifier was very similar to a previously described "ABMR probability" classifier trained on histologic ABMR in transcript associations and prediction of molecular or histologic ABMR. Plotting the biopsies using Uniform Manifold Approximation and Projection revealed a gradient of increasing molecular ABMR-like transcript expression in NR biopsies, associated with increased DSA (P<2 × 10-16). In biopsies with no molecular or histologic rejection, increased DSAProb or ABMR probability scores were associated with increased risk of kidney failure over 3 years. CONCLUSIONS: Many biopsies currently considered to have no molecular or histologic rejection have mild increases in expression of ABMR-related transcripts, associated with increasing frequency of DSA. Thus, mild molecular ABMR-related pathology is more common than previously realized.
BACKGROUND: Donor -specific HLA antibody (DSA) is present in many kidney transplant patients whose biopsies are classified as no rejection (NR). We explored whether in some NR kidneys DSA has subtle effects not currently being recognized. METHODS: We used microarrays to examine the relationship between standard-of-care DSA and rejection-related transcript increases in 1679 kidney transplant indication biopsies in the INTERCOMEX study (ClinicalTrials.gov NCT01299168), focusing on biopsies classified as NR by automatically assigned archetypal clustering. DSA testing results were available for 835 NR biopsies and were positive in 271 (32%). RESULTS: DSA positivity in NR biopsies was associated with mildly increased expression of antibody-mediated rejection (ABMR)-related transcripts, particularly IFNG-inducible and NK cell transcripts. We developed a machine learning DSA probability (DSAProb) classifier based on transcript expression in biopsies from DSA-positive versus DSA-negative patients, assigning scores using 10-fold cross-validation. This DSAProb classifier was very similar to a previously described "ABMR probability" classifier trained on histologic ABMR in transcript associations and prediction of molecular or histologic ABMR. Plotting the biopsies using Uniform Manifold Approximation and Projection revealed a gradient of increasing molecular ABMR-like transcript expression in NR biopsies, associated with increased DSA (P<2 × 10-16). In biopsies with no molecular or histologic rejection, increased DSAProb or ABMR probability scores were associated with increased risk of kidney failure over 3 years. CONCLUSIONS: Many biopsies currently considered to have no molecular or histologic rejection have mild increases in expression of ABMR-related transcripts, associated with increasing frequency of DSA. Thus, mild molecular ABMR-related pathology is more common than previously realized.
Authors: P F Halloran; J Reeve; E Akalin; O Aubert; G A Bohmig; D Brennan; J Bromberg; G Einecke; F Eskandary; C Gosset; J-P Duong Van Huyen; G Gupta; C Lefaucheur; A Malone; R B Mannon; D Seron; J Sellares; M Weir; A Loupy Journal: Am J Transplant Date: 2017-05-30 Impact factor: 8.086
Authors: Jeff Reeve; Georg A Böhmig; Farsad Eskandary; Gunilla Einecke; Gaurav Gupta; Katelynn Madill-Thomsen; Martina Mackova; Philip F Halloran Journal: Am J Transplant Date: 2019-04-10 Impact factor: 8.086
Authors: G Einecke; B Sis; J Reeve; M Mengel; P M Campbell; L G Hidalgo; B Kaplan; P F Halloran Journal: Am J Transplant Date: 2009-11 Impact factor: 8.086
Authors: Christoph A Diebolder; Frank J Beurskens; Rob N de Jong; Roman I Koning; Kristin Strumane; Margaret A Lindorfer; Marleen Voorhorst; Deniz Ugurlar; Sara Rosati; Albert J R Heck; Jan G J van de Winkel; Ian A Wilson; Abraham J Koster; Ronald P Taylor; Erica Ollmann Saphire; Dennis R Burton; Janine Schuurman; Piet Gros; Paul W H I Parren Journal: Science Date: 2014-03-14 Impact factor: 47.728
Authors: Imran J Anwar; Isabel F DeLaura; Qimeng Gao; Joseph Ladowski; Annette M Jackson; Jean Kwun; Stuart J Knechtle Journal: Front Immunol Date: 2022-06-09 Impact factor: 8.786
Authors: Lisa K Seiler; Ngoc Linh Phung; Christoph Nikolin; Stephan Immenschuh; Christian Erck; Jessica Kaufeld; Hermann Haller; Christine S Falk; Rebecca Jonczyk; Patrick Lindner; Stefanie Thoms; Julia Siegl; Günter Mayer; Regina Feederle; Cornelia A Blume Journal: Diagnostics (Basel) Date: 2022-01-25
Authors: Philip F Halloran; Jeff Reeve; Katelynn S Madill-Thomsen; Zachary Demko; Adam Prewett; Paul Billings Journal: J Am Soc Nephrol Date: 2022-01-20 Impact factor: 10.121
Authors: Elisabet Van Loon; Baptiste Lamarthée; Henriette de Loor; Amaryllis H Van Craenenbroeck; Sophie Brouard; Richard Danger; Magali Giral; Jasper Callemeyn; Claire Tinel; Álvaro Cortés Calabuig; Priyanka Koshy; Ben Sprangers; Dirk Kuypers; Wilfried Gwinner; Dany Anglicheau; Pierre Marquet; Maarten Naesens Journal: Kidney Int Date: 2022-05-05 Impact factor: 18.998
Authors: Philip F Halloran; Katelynn S Madill-Thomsen; Shane Pon; Majid L N Sikosana; Georg A Böhmig; Jonathan Bromberg; Gunilla Einecke; Farsad Eskandary; Gaurav Gupta; Luis G Hidalgo; Marek Myslak; Ondrej Viklicky; Agnieszka Perkowska-Ptasinska Journal: Am J Transplant Date: 2022-06-02 Impact factor: 9.369